Company intelligence / Profile preview
Alzinova AB
Mölndal, Västra Götaland, Swedenalzinova.com ↗
- Ownership
- Public · ALZ
- Employees
- ~5
- Development stage
- Phase 1
01
Overview
The company’s lead candidate, ALZ‑101, a therapeutic vaccine targeting amyloid-beta oligomers in Alzheimer’s disease, has completed part A of a phase 1b study with favorable safety and tolerability results and a high immune responder rate. Antibody levels increased with dosing. An extension study at higher doses is ongoing. Preparations for phase 2 are underway following positive regulatory feedback from FDA and EMA. The monoclonal antibody program ALZ‑201 remains in preclinical development[6][7][8][10].
- Therapeutic areas
- Neurology
- Modalities
- Active immunotherapies (therapeutic vaccines)Passive immunotherapies (monoclonal antibodies)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
PolyPeptide Laboratories (manufacturing partner for clinical trial material)[8]
04
Financials
- Market cap
- $10.7M
- Total revenue
- $0
- Enterprise value
- $9.4M
Beyond the preview
Go deeper on Alzinova AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alzinova AB.